RBC Capital Initiates Coverage on OncoGenex Pharmaceuticals (OGXI) with an Outperform
More News related to OGXI
- Wedbush Maintains an 'Outperform' on OncoGenex Pharmaceuticals (OGXI); Removes From Best Ideas List
- OncoGenex Pharma (OGXI) OGX-427 Phase 2 Receives Grant Funding
- OncoGenex Announces that a Randomized, Investigator-Sponsored Phase 2 Study Evaluating OGX-427 has Received Grant Funding
- Wedbush Maintains an 'Outperform' on OncoGenex Pharmaceuticals (OGXI); Raises Fair Valur
- Unusual 11 Mid-Day Movers 12/21: ATHX, AMFI, CHTT, TMS, ADES Higher; OGXI, GIGM, PCBC, XRA Lower
More News related to New Coverage
- Janney Montgomery Scott Initiates Coverage on Papa John's International (PZZA) with a Neutral
- Feltl & Co. Initiates Coverage on ActivIdentity (ACTI) with a Buy
- Oscar Gruss Initiates Coverage Airgas (ARG) with a Buy
- Sidoti & Co Initiates Coverage on Solutia (SOA) with a Buy
- RBC Capital Initiates Coverage on Questar (STR) with a Sector Perform
RBC Capital initiates coverage on OncoGenex Pharmaceuticals (Nasdaq: OGXI) with an Outperform rating. Price target $65.
To see more analyst ratings on OGXI Click Here.
OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for the treatment of cancer.
Related Categories
New CoverageStocks Mentioned
+0.77Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
